Analyst Price Targets — BBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:31 pm | Danielle Brill | Truist Financial | $95.00 | $65.75 | TheFly | BridgeBio price target raised to $95 from $86 at Truist |
| February 17, 2026 11:09 am | Raghuram Selvaraju | H.C. Wainwright | $100.00 | $75.25 | TheFly | BridgeBio price target raised to $100 from $90 at H.C. Wainwright |
| February 13, 2026 2:06 pm | William Pickering | Tudor Pickering | $100.00 | $76.59 | TheFly | BridgeBio price target raised to $100 from $94 at Bernstein |
| February 13, 2026 1:10 pm | Trevor Allred | Oppenheimer | $83.00 | $76.22 | TheFly | BridgeBio price target raised to $83 from $81 at Oppenheimer |
| February 12, 2026 7:07 pm | Andrew Tsai | Jefferies | $100.00 | $76.06 | TheFly | BridgeBio price target raised to $100 from $85 at Jefferies |
| February 12, 2026 3:03 pm | Martin Auster | Raymond James | $89.00 | $77.74 | StreetInsider | BridgeBio Pharma (BBIO) PT Raised to $89 at Raymond James |
| January 27, 2026 9:24 pm | — | Barclays | $157.00 | $77.87 | TheFly | BridgeBio initiated with an Overweight at Barclays |
| January 20, 2026 11:14 am | Tiago Fauth | Wells Fargo | $88.00 | $76.26 | TheFly | BridgeBio price target raised to $88 from $84 at Wells Fargo |
| January 8, 2026 12:53 pm | — | Truist Financial | $86.00 | $74.27 | TheFly | BridgeBio price target raised to $86 from $80 at Truist |
| January 6, 2026 10:09 am | — | Morgan Stanley | $96.00 | $73.42 | TheFly | BridgeBio initiated with an Overweight at Morgan Stanley |
Latest News for BBIO
BridgeBio Pharma (NASDAQ: BBIO) CEO Neil Kumar outlined the company's recent clinical progress, commercial momentum, and near-term regulatory plans during a fireside chat at TD Cowen's 46th Annual Healthcare Conference, while also addressing investor focus on a pending intellectual property trial related to tafamidis. Stock pullback and the tafamidis IP overhang Kumar said the company has
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a…
BridgeBio Pharma (BBIO) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to a loss of $1.31 per share a year ago.
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
PALO ALTO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on Attruby's commercial progress.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BBIO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.